Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112005 · ClinicalTrials.gov registry record
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
A clinical trial of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Eyenuk.
- Completed
- Registry status
- 942
- Enrollment target
- 1
- Study location
NCT03112005: Completed study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Eyenuk.
NCT03112005 is a study of Diabetic Macular Edema and Diabetic Retinopathy that has completed, run by Eyenuk. The registered enrollment target is 942 participants, below the 3,779-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03112005, a study of Diabetic Macular Edema and Diabetic Retinopathy, has completed, sponsored by Eyenuk.
- COMPLETED
- Registry status
- 942 participants
- Enrollment target
- 1
- Study location
Study Summary
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommended for all diabetic patients since vision loss can be prevented with laser photocoagulation and anti-VEGF treatment if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is orders of magnitude smaller than that needed to screen the large, growing diabetic population. Therefore, to meet this large unmet need for DR screening, a fully-automated computerized DR screening system is necessary. EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.
Primary Outcome
The performance of EyeArt will be evaluated using sensitivity and specificity measures.
Conditions Studied
Interventions
- PROCEDURE Color fundus photography
- DRUG Mydriatic Agent
Study Locations (1)
California
- Los Angeles Biomedical Research Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2018-05-31 |
What the finished NCT03112005 record still lists
NCT03112005 is an observational study that tracks outcomes without assigning an intervention. The registered 942 participants enrollment target is mid-sized for trials with a published cap, below the 3,779-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Color fundus photography is the first listed.
NCT03112005 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03112005 about?
NCT03112005 is a clinical study titled "Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool". More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommen...
What is the current status of trial NCT03112005?
This trial is currently completed. The enrollment target is 942 participants. The study started on 2017-04-17. Estimated completion is 2018-05-31.
What conditions does trial NCT03112005 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy, Diabetic Eye Problems.
What interventions are being tested in trial NCT03112005?
The interventions under investigation include: Color fundus photography (PROCEDURE), Mydriatic Agent (DRUG).
Who is sponsoring clinical trial NCT03112005?
This trial is sponsored by Eyenuk, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03112005 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03112005's enrollment target sits among peer trials
942 5th of 63 higher than 59 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI